EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($1.09), $0.15 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $507 thousand versus the consensus estimate of $383 thousand.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.